Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that recombinant human ADM2 treatment inhibited cell proliferation and induced apoptosis in human hair follicles, contrasting with the previously documented pro-proliferative and anti-apoptotic functions of ADM2.

In this study, 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17.beta.-carboxamides were synthesized and evaluated in vitro as potential 5 alpha-reductase inhibitors and antiandrogens.

This study found that androsterone glucuronate (ADT-G) was the only androgenic metabolite sensitive to detecting differences between adult women with acne and controls, and its levels decreased with systemic treatment.

This study suggests that androgen receptor CAG polymorphisms may not significantly influence androgenetic alopecia susceptibility in Korean men.

In this study, researchers found that the JAK1/2 inhibitor ruxolitinib helped normalize tissue-specific autoimmunity in APECED patients by reducing inflammation and immune cell accumulation, but it was also linked to subclinical side effects like anemia and weight gain.

This article highlights the importance of early diagnosis and management of certain cutaneous adverse drug reactions and autoimmune disorders in dermatological emergencies, but it reports no new clinical results.

This study found that early treatment of alopecia areata with JAK inhibitors can improve patients' physical and psychological quality of life without worsening skin lesions associated with sarcoidosis.

In this real-world study, aumolertinib was found to improve patient-reported outcomes and maintain high disease control and objective response rates similar to those reported in the AENEAS trial for advanced NSCLC patients, supporting its use in first-line treatment.

5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.

This case report describes successful treatment of anaplasmosis in a Kintamani mix dog with doxycycline, ivermectin, vetadryl, and Livron b-plex, leading to improved activity, hair growth, appetite, and tick eradication.

This study found that testosterone and its metabolite DHT reduced macrophage-mediated phagocytosis of bacteria like MRSA and P. aeruginosa in vitro, and blocking testosterone's conversion to DHT improved bacterial clearance, suggesting potential therapeutic strategies for combating wound infections in the elderly.

This study found that the AR-E211 A allele is associated with a lower risk of both metastatic prostate cancer and androgenetic alopecia in an Australian population.

In this study, network meta-analyses were used to explore the ranking of various 5-alpha reductase inhibitor regimens on reducing dihydrotestosterone levels and to investigate whether this reduction correlates with increased total hair density in male androgenetic alopecia.

The researchers reported that disrupting ATRA signaling by deleting RDHE genes in the hair follicle led to altered hair follicle cycles, composition, and gene expression, indicating RDHEs' role in hair follicle signaling coordination.

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

This review discusses recent research and applications of RADA16 and RADA16-based peptide scaffolds in biomedicine, including their roles in tissue repair and drug delivery, but reports no new clinical results.

DACC-based dressings are more effective than silver-based ones for treating chronic wounds with antimicrobial resistance.

This article discusses the approval status of 5α-reductase inhibitors for androgenetic alopecia, noting finasteride is FDA-approved for certain men while dutasteride is not approved in the US for this condition; it reports no new results.

This study found that men using 5-alpha-reductase inhibitors showed an increased risk for dementia shortly after starting treatment, which diminished over time, and a consistent association with depression, but no link to suicide.

This study found that abietic acid from pine resin more effectively inhibits testosterone 5α-reductase than several plant extracts, suggesting potential for treating androgen-dependent diseases.

This study investigates the potential of onion extract as a treatment for androgenetic alopecia by using in silico and ADME/T analyses to examine how active compounds from onions interact with the 5-alpha-reductase enzyme.

In this study, researchers used a computational drug repurposing approach to identify FDA-approved drugs Dutasteride and Solifenacin as potential inhibitors of Listeria monocytogenes via binding to the virulence factor regulator PrfA, suggesting they may offer new treatment strategies against multi-drug resistant strains.

In this review, the authors detailed various dermatologic adverse events associated with aromatase inhibitors in postmenopausal women and discussed strategies to potentially prevent these events, aiming to minimize interruptions in breast cancer treatment.

AKR1B10 enzyme may cause keloid scars and could be a treatment target.

This study found that the methanolic extract of Carduus adpressus exhibited strong antibacterial, antioxidant, and wound-healing activities, suggesting its potential use in developing wound-healing agents.

This study found that ion-paired solutions significantly improved the skin penetration of risedronate in hairless mice compared to risedronate alone.

This study found that abrocitinib showed promising efficacy and safety in adolescents with moderate-to-severe alopecia areata, with significant hair regrowth observed over 10 months of treatment.

This study used the "ARE-Luc" mouse model to visualize androgen receptor activity across various tissues in both male and female mice, highlighting the direct action of androgens outside reproductive organs.

This study provides insight into AR-mediated gene activation and the molecular mechanisms of prostate cancer progression and drug resistance, identifying potential avenues for developing new therapies.

This case study reported significant clinical improvement in a 26-year-old male with dissecting cellulitis of the scalp after treatment with upadacitinib, suggesting that JAK inhibitors may be a promising option for refractory cases, where standard treatments have limited success.